Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TROV - Trovagene Inc.

Previous close
1.19
1.190   100.000%

Share volume: 0
Last Updated: Thu 07 May 2020 10:00:00 PM CEST
Medical/Nursing Services: 0%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
30%
Profitability 25%
Dept financing 4%
Liquidity 75%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$1.19
P/E Ratio 
N/A
DAY RANGE
$1.19 - $1.19
EPS 
-$3.03
52 WEEK RANGE
$0.70 - $3.46
52 WEEK CHANGE
-$63.61
MARKET CAP 
14.180 M
YIELD 
N/A
SHARES OUTSTANDING 
11.916 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$11,294,712
AVERAGE 10 VOLUME 
$1,707,989
AVERAGE 30 VOLUME 
$697,369
Company detail
CEO: Thomas H. Adams
Region: US
Website: http://www.trovagene.com
Employees: 14
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Medical/Nursing Services
Sector: Health Services

Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Recent news